Are peptide conjugates the golden therapy against obesity?

The Journal of Endocrinology
S J BrandtTimo D Müller

Abstract

Obesity is a worldwide pandemic, which can be fatal for the most extremely affected individuals. Lifestyle interventions such as diet and exercise are largely ineffective and current anti-obesity medications offer little in the way of significant or sustained weight loss. Bariatric surgery is effective, but largely restricted to only a small subset of extremely obese patients. While the hormonal factors mediating sustained weight loss and remission of diabetes by bariatric surgery remain elusive, a new class of polypharmacological drugs shows potential to shrink the gap in efficacy between a surgery and pharmacology. In essence, this new class of drugs combines the beneficial effects of several independent hormones into a single entity, thereby combining their metabolic efficacy to improve systems metabolism. Such unimolecular drugs include single molecules with agonism at the receptors for glucagon, glucagon-like peptide 1 and the glucose-dependent insulinotropic polypeptide. In preclinical studies, these specially tailored multiagonists outperform both their mono-agonist components and current best in class anti-obesity medications. While clinical trials and vigorous safety analyses are ongoing, these drugs are poised to have...Continue Reading

References

Jul 16, 1970·The New England Journal of Medicine·W A MüllerR H Unger
Apr 1, 1970·The Journal of Clinical Investigation·R H UngerA M Eisentraut
Jun 1, 1995·Journal of the American Dietetic Association·J C BurgeL Flancbaum
Dec 1, 1994·Metabolism: Clinical and Experimental·D KelleyT Veneman
Feb 1, 1994·Obesity Surgery·D M ScruggsG S Cowan
Jun 1, 2002·European Journal of Endocrinology·Hongxiang HuiRiccardo Perfetti
Jun 18, 2002·Nature Medicine·Kazumasa MiyawakiYutaka Seino
Feb 6, 2003·Obesity Surgery·Henry Buchwald
Oct 14, 2004·JAMA : the Journal of the American Medical Association·Henry BuchwaldKaren Schoelles
Dec 24, 2004·The New England Journal of Medicine·Lars SjöströmUNKNOWN Swedish Obese Subjects Study Scientific Group
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
May 9, 2006·Biological Reviews of the Cambridge Philosophical Society·Jonathan C K Wells
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Jul 11, 2007·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Pengyun LiFaming Zhang
Jul 15, 2009·Nature Chemical Biology·Jonathan W DayMatthias H Tschöp
Jul 16, 2009·Diabetes·Alessandro PocaiRanabir SinhaRoy
Nov 11, 2009·Current Opinion in Gastroenterology·Alexander D Miras, Carel W le Roux
Aug 27, 2010·The American Journal of Clinical Nutrition·Elizabeth A OdstrcilJohn S Fordtran
Dec 7, 2010·Journal of Diabetes Science and Technology·Joseph R ChabenneRichard D DiMarchi
Sep 23, 2011·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A C Shin, H-R Berthoud
Sep 22, 2011·Diabetes Technology & Therapeutics·Brooke E BayhamCarol E O'Neil
Nov 30, 2011·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A LaureniusT Olbers
Jan 5, 2012·The Journal of Clinical Investigation·Roger H Unger, Alan D Cherrington
Sep 5, 2012·Nature Reviews. Endocrinology·Juris J Meier

❮ Previous
Next ❯

Citations

Apr 17, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·David M WilliamsMarc Evans
Dec 17, 2020·Frontiers in Endocrinology·L KořínkováLenka Maletínská
Mar 10, 2020·Peptides·Mohan PatilGanesh V Sangle
Jun 29, 2021·Expert Opinion on Emerging Drugs·Mathies M Jepsen, Mikkel B Christensen
Aug 6, 2021·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·Adina Sophie GraffunderHeike Biebermann

❮ Previous
Next ❯

Methods Mentioned

BETA
gastric bypass
acylation
pharmacotherapies

Software Mentioned

DualAG

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.